Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Guayusa extract is a caffeinated Amazonian 'super-leaf' belonging to the holly species that contains a very unique blend of polyphenol antioxidants and caffeine (~20% caffeine, 30% chlorogenic acids, 5% catechins). It is also remarkably low in tannins which are responsible for the bitter taste found in most teas - giving it a sweet flavor profile. As such, it is marketed as an ingredient that can help support energy and performance with potential health-related benefits due to its antioxidant properties. Indeed, ingredients such as these are often consumed by individuals prior to exercise in order to help improve exercise performance, or otherwise to support health-related goals. Whereas several studies have suggested that caffeine and chlorogenic acid consumption may improve performance, mood, and concentration, and some evidence in animals have linked catechin consumption to improved health outcomes, no studies have previous studied whether guayusa extract supplementation helps to support exercise performance in humans. In this study, we will test the whether dietary supplementation with the botanical organic guayusa extract helps support (1) the desire to exercise and exercise performance throughout a 6-week high intensity exercise training program, and thus (2) helps support the physiological adaptations (including body composition, fasting metabolic biomarkers, blood pressure and heart rate, submaximal and maximal exercise performance and fuel metabolism, and changes in the gut microbiome/mycobiome) to a 6-week high intensity exercise training program.
Question 1: Does organic guayusa extract supplementation support the desire to train and training load in physically-active women performing a high-intensity exercise training program?
Question 2: Does organic guayusa extract supplementation support physiological adaptation to exercise (including body composition, fasting metabolic biomarkers, blood pressure and heart rate, submaximal and maximal exercise performance and fuel metabolism, and changes in the gut microbiome/mycobiome) in physically-active women performing a high-intensity exercise training program?
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Organic Guayusa Extract + High Intensity Exercise | Experimental | Participants will consume an organic guayusa extract supplement that contains caffeine and antioxidants each day for 6 weeks while completing the exercise training program on 3 days/week. On days that participants exercise, they will consume the supplement 30-60 minutes before exercise training. On days they do not exercise, they will consume the capsules upon waking. |
|
| Placebo + High Intensity Exercise | Placebo Comparator | Participants will consume a placebo consisting of maltodextrin each day for 6 weeks while completing the exercise training program. The placebo will be provided in capsule identical in appearance to the active supplement. On days that participants exercise, they will consume the placebo 30-60 minutes before exercise training. On days they do not exercise, they will consume the capsules upon waking. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Organic Guayusa Extract | Dietary Supplement | Supplementation: Participants will supplement daily with organic guayusa extract, which is a caffeinated Amazonian 'super-leaf' belonging to the holly species that contains a very unique blend of polyphenol antioxidants and caffeine (~20% caffeine, 30% chlorogenic acids, 5% catechins) during 6 weeks of high intensity exercise training. Investigators and participants will be blinded to condition. |
| Measure | Description | Time Frame |
|---|---|---|
| Desire to Exercise | Desire to Exercise will be assessed Primarily via the Assessment of Exercise Readiness using a 41-item Exercise Readiness Questionnaire. | Throughout 6-week training period. |
| Exercise Adherence | Exercise training session adherence will be assessed across all exercise training sessions as a primary quantitative indicator of desire to exercise. Adherence will be assessed as the actual number of completed exercise sessions among participants in each group relative (i.e., percent, %) to the number of total planned exercise sessions. Group differences in session adherence will be compared by chi squared tests. | Throughout 6-week training period. |
| Exercise Training Load | Resistance Exercise Training Volume (normalized to bodyweight) will be quantified in each resistance training workout (2x/week) and used as a quantitative indicator of exercise performance/effort. | Throughout 6-week training period. |
| Measure | Description | Time Frame |
|---|---|---|
| Desire to Exercise Secondary Measures | Secondary assessments of Desire to Exercise will include visual analog scales (range 0 - 50, with 0 indicating lower desire and 50 indicating higher desire) used to assess readiness immediately before exercise sessions to "exercise right now", to "invest physical energy right now" and to "invest mental energy right now". | Throughout 6-week training period. |
| Measure | Description | Time Frame |
|---|---|---|
| Rating of Perceived Exertion | RPE will be assessed following each exercise session to determine subjective effort for each session on a scale of 1-10, where 1 is lowest perceived effort (e.g., rest) and 10 is greatest perceived effort. | Throughout 6-week training period. |
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Integrative Laboratory of Applied Physiology and Lifestyle Medicine | Iowa City | Iowa | 52242 | United States |
Not provided
Randomized, Double-Blind, Placebo Controlled, Parallel Arm Trial
Not provided
Not provided
Not provided
|
| Placebo | Dietary Supplement | Participants will supplement daily with placebo (maltodextrin). Investigators and participants will be blinded to condition. |
|
| Exercise Training Performance | Secondary assessments of exercise training performance will include performance during a) a weekly airbike interval exercise session (Avg W), b) a weekly 500 m row (time to completion, Avg W), and c) the time (min) taken to complete the weekly metabolic conditioning workout. | Throughout 6-week training period. |
| VO2peak | VO2peak will be assessed during a ramp test on a electronically-braked cycle ergometer performed to volitional exhaustion with pulmonary gas exchange analysis. | baseline, <7 days after completing the intervention |
| Submaximal Exercise Fat Oxidation | Submaximal Exercise Fat Oxidation (%) will be assessed during exercise at a fixed power (i.e., 75W) on an electronically-braked cycle ergometer with pulmonary gas exchange analysis. | baseline, <7 days after completing the intervention |
| Submaximal Exercise Blood Pressure | Submaximal Systolic and Diastolic Exercise Blood Pressure (mmHg) will be assessed during exercise at a fixed power (75W) on an electronically-braked cycle ergometer. | baseline, <7 days after completing the intervention |
| Fasting metabolic biomarkers | Total cholesterol, HDL-cholesterol, LDL-cholesterol, non-HDL cholesterol, triglycerides, glucose, insulin, c-peptide, GLP-1, GIP | baseline, <7 days after completing the intervention |
| Fasting total cholesterol | Total cholesterol will be assessed from a fasting blood sample. | baseline, <7 days after completing the intervention |
| Fasting HDL-cholesterol | HDL-cholesterol will be assessed from a fasting blood sample. | baseline, <7 days after completing the intervention |
| Fasting non-HDL cholesterol | Non-HDL cholesterol will be assessed from a fasting blood sample. | baseline, <7 days after completing the intervention |
| Fasting triglycerides | Triglycerides will be assessed from a fasting blood sample | baseline, <7 days after completing the intervention |
| Fasting Glucose | Glucose will be assessed from a fasting blood sample | baseline, <7 days after completing the intervention |
| Fasting insulin | insulin will be assessed from a fasting blood sample | baseline, <7 days after completing the intervention |
| Fasting c-peptide | Fasting c-peptide will be assessed from a fasting blood sample | baseline, <7 days after completing the intervention |
| Fasting GLP-1 | Fasting GLP-1 will be assessed from a fasting blood sample | baseline, <7 days after completing the intervention |
| Fasting GIP | Fasting GIP will be assessed from a fasting blood sample | baseline, <7 days after completing the intervention |
| Fasting IL-6 | IL-6 will be assessed from a fasting blood sample | baseline, at 1 week during the intervention, <7 days after completing the intervention |
| Fasting IL-10 | IL-10 will be assessed from a fasting blood sample | baseline, at 1 week during the intervention, <7 days after completing the intervention |
| Fasting TNFa | TNFa will be assessed from a fasting blood sample | baseline, at 1 week during the intervention, <7 days after completing the intervention |
| Fasting triiodothyronine (T3) | Triiodothyronine (T3) will be assessed from a fasting blood sample | baseline, at 1 week during the intervention, <7 days after completing the intervention |
| Fasting thyroxine (T4) | Thyroxine (T4) will be assessed from a fasting blood sample | baseline, at 1 week during the intervention, <7 days after completing the intervention |
| Fasting Progesterone | Progesterone will be assessed from a fasting blood sample | baseline, at 1 week during the intervention, <7 days after completing the intervention |
| Fasting Testosterone | Testosterone will be assessed from a fasting blood sample | baseline, at 1 week during the intervention, <7 days after completing the intervention |
| Fasting Estrogen | Estrogen will be assessed from a fasting blood sample | baseline, at 1 week during the intervention, <7 days after completing the intervention |
| Fasting Cortisol | Cortisol will be assessed from a fasting blood sample | baseline, at 1 week during the intervention, <7 days after completing the intervention |
| Fasting Adiponectin | Adiponectin will be assessed from a fasting blood sample | baseline, <7 days after completing the intervention |
| Fasting Leptin | Leptin will be assessed from a fasting blood sample | baseline, <7 days after completing the intervention |
| Fasting Adipsin | Adipsin will be assessed from a fasting blood sample | baseline, <7 days after completing the intervention |
| Fasting Lipocalin | Lipocalin will be assessed from a fasting blood sample | baseline, <7 days after completing the intervention |
| Fasting Plasminogen activator inhibitor-1 (PAI-1) | Plasminogen activator inhibitor-1 (PAI-1) will be assessed from a fasting blood sample | baseline, <7 days after completing the intervention |
| Fasting Resistin | Resistin will be assessed from a fasting blood sample | baseline, <7 days after completing the intervention |